33 completed, 14 recruiting, 12 active not recruiting, 12 terminated. 40 Phase 2, 26 Phase 1, 11 Not applicable, 6 Phase 3.
Follow GastroEsophageal Cancer: new trials by email Literature Review of GastroEsophageal Cancer trials Research Report on GastroEsophageal Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA Zanidatamab - Esophageal Cancer, GastroEsophageal Cancer | Not yet recruiting | Jazz Pharmaceuticals | 300 | 2026-11-30 | 2026-10-26 | |
| A Study of MGC030 in Participants With Advanced Solid Tumors MGC030 - Urothelial Cancer, GastroEsophageal Cancer | Phase 1 | Recruiting | MacroGenics | 314 | 2026-10-07 | 2026-10-30 |
| Perioperative Zanidatamab and Chemotherapy for HER2 Positive Gastroesophageal Cancer Zanidatamab Combined with Chemotherapy - Gastroesophageal Cancer | Phase 1 / Phase 2 | Not yet recruiting | Universitaire Ziekenhuizen KU Leuven | 29 | 2026-06-01 | 2026-03-20 |
| A First-In-Human Phase I/IIa Study to Evaluate DA 3501 in Patients With Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma and Pancreatic Ductal Adenocarcinoma DA-3501 - Gastric (Stomach) Cancer, GastroEsophageal Cancer | Phase 1 | Recruiting | Dong-A ST Co., Ltd. | 51 | 2026-05-18 | 2026-05-20 |
| Peri-operative Treatment of Resectable Gastroesophageal Cancer Using Bemarituzumab (BEMA) Plus Perioperative Treatment Bemarituzumab, FLOT - GastroEsophageal Cancer | Phase 1 | Not yet recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 27 | 2026-02-20 | 2025-06-05 |
| A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer nivolumab, ipilimumab - Colorectal Cancer, Gastroesophageal Cancer | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2025-09-09 | 2025-09-11 | |
| Sample Collection for Ongoing Research and Product Evaluation Study Breast Cancer, Lung Cancer | Recruiting | Natera, Inc. | 9600 | 2025-07-21 | 2026-01-15 | |
| PULSO Trial: Pulsed Low-Dose-Rate (PLDR) Radiation Chemoradiation (CRT) vs. Standard CRT for Esophageal Cancer Induction Chemotherapy (modified FLOT or modified FOLFOX-6), Chemotherapy, Conventional Radiation - Esophageal Cancer, Oesophageal Cancer | Phase 2 | Recruiting | Medical College of Wisconsin | 50 | 2025-06-17 | 2026-07-28 |
| Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON) Immune checkpoint inhibitor (ICI) or chemotherapy alone - GastroEsophageal Cancer | Withdrawn | Duke University | 2025-04-16 | 2026-01-29 | ||
| Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer Docetaxel, Oxaliplatin, Leucovorin - Gastric Cancer, Stomach Cancer | Phase 2 / Phase 3 | Recruiting | Ukrainian Society of Clinical Oncology | 150 | 2025-03-25 | 2025-05-06 |
| A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors Zanidatamab - Breast Cancer, Gastric Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 200 | 2025-01-14 | 2026-07-10 |
| A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers Extended Dosing Interval - A, Extended Dosing Interval - B, Extended Dosing Interval - C - Carcinoma, Hepatocellular, Gastric Adenocarcinoma | Phase 2 | Recruiting | National University Hospital, Singapore | 360 | 2024-11-25 | 2025-01-10 |
| Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer Local treatment (Surgical), PD-1 Monoclonal Antibody, XELOX/SOX Chemotherapy Regimen - Gastric Cancer, GastroEsophageal Cancer | Phase 2 | Recruiting | Shanghai Zhongshan Hospital | 84 | 2024-11-08 | 2026-01-21 |
| Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer Dietitian Consultation, Survey, Fitbit Data Collection - GastroEsophageal Cancer | Not applicable | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 80 | 2024-07-26 | 2026-04-01 |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors MDX2001 - Biliary Tract Cancer, Breast Cancer | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 330 | 2024-06-12 | 2026-10-15 |
| A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) Sacituzumab tirumotecan, Trifluridine-Tipiracil, Irinotecan - Gastroesophageal Cancer | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 473 | 2024-05-03 | 2026-10-22 |
| A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors BG-68501, Fulvestrant, BGB-43395 - Breast Cancer, Small Cell Lung Cancer | Phase 1 | Active not recruiting | BeiGene | 103 | 2024-03-11 | 2026-10-20 |
| Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction，a Phase II Clinical Study Sintilimab,nab-paclitaxel and tegio - Gastric Cancer, GastroEsophageal Cancer | Phase 2 | Not yet recruiting | Wu Jun | 40 | 2024-02-03 | 2024-02-05 |
| Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer Neratinib, Trastuzumab, Oxaliplatin - GastroEsophageal Cancer, Gastric Cancer | Phase 2 | Active not recruiting | H. Lee Moffitt Cancer Center and Research Institute | 8 | 2024-01-12 | 2026-06-12 |
| A Study of Minimally Invasive Proximal Gastrectomy Versus Minimally Invasive Total Gastrectomy for Gastric and Gastroesophageal Junction Cancers MDASI-GI - Gastric Cancer, GastroEsophageal Cancer | Active not recruiting | Memorial Sloan Kettering Cancer Center | 4 | 2024-01-08 | 2026-07-22 |
Showing 20 of 85. Sign in to see all of them.
Stomach Neoplasms (35) · Esophageal Neoplasms (22) · Carcinoma, Non-Small-Cell Lung (13) · Colorectal Neoplasms (11) · Ovarian Neoplasms (11) · Breast Neoplasms (10) · Pancreatic Neoplasms (10) · Endometrial Neoplasms (8) · Triple Negative Breast Neoplasms (8) · Carcinoma, Renal Cell (7) · Melanoma (6) · Urinary Bladder Neoplasms (6) · Adenocarcinoma (5) · Carcinoma, Transitional Cell (5) · Neoplasms (5)
Neoplasms by Site (63) · Neoplasms (59) · Digestive System Diseases (58) · Digestive System Neoplasms (58) · Gastrointestinal Diseases (58) · Gastrointestinal Neoplasms (57) · Stomach Diseases (35) · Head and Neck Neoplasms (24) · Esophageal Diseases (22) · Neoplasms by Histologic Type (21) · Carcinoma (18) · Neoplasms, Glandular and Epithelial (18) · Endocrine Gland Neoplasms (17) · Endocrine System Diseases (17) · Female Urogenital Diseases (17)
Oxaliplatin (13) · pembrolizumab (12) · Paclitaxel (11) · Fluorouracil (10) · Nivolumab (8) · Leucovorin (7) · Capecitabine (6) · Carboplatin (6) · Irinotecan (5) · Trastuzumab (5) · Ipilimumab (4) · Surgical Procedures, Operative (4) · durvalumab (4) · Albumin-Bound Paclitaxel (3) · Docetaxel (3)
H. Lee Moffitt Cancer Center and Research Institute (3) · Leap Therapeutics, Inc. (3) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · University of California, Irvine (3) · AIO-Studien-gGmbH (2) · Arcus Biosciences, Inc. (2) · AstraZeneca (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · Jazz Pharmaceuticals (2) · Jiangsu HengRui Medicine Co., Ltd. (2) · M.D. Anderson Cancer Center (2) · Massachusetts General Hospital (2) · Memorial Sloan Kettering Cancer Center (2) · SCRI Development Innovations, LLC (2) · ADC Therapeutics S.A. (1)
United States (52) · China (12) · Germany (7) · South Korea (7) · France (5) · Spain (5) · Australia (4) · Belgium (4) · Canada (4) · Israel (4) · Italy (3) · Japan (3) · Taiwan (3) · United Kingdom (3) · Brazil (2)
Farshid Dayyani, MD, PhD (2) · Markus Moehler (2) · Vincent Lam, MD (2) · Ajay K Kakkar, PhD (1) · Alexander Stein, Dr. (1) · Amir Alishahi Tabriz, MD, PhD, MPH (1) · Anthony Elias, MD (1) · Antoine Adenis, MD, PhD (1) · Arlette Da Silva, MD (1) · Cyndi Sirard, MD (1) · Cynthia Sirard, MD (1) · Dae Won Kim, MD (1) · David Spigel, M.D. (1)
PMID 23975663, PMID 25694417, PMID 29218623, PMID 29235564, PMID 29362244, PMID 29880231, PMID 30373600, PMID 30871493, PMID 31221115, PMID 31582355, PMID 32127922, PMID 32487035, PMID 33026938, PMID 33766817, PMID 33789008, PMID 34330715, PMID 35387780, PMID 35397575, PMID 35737383, PMID 36098320, PMID 37653380, PMID 38341203, PMID 38504015, PMID 38823034, PMID 39097500, PMID 39432867, PMID 39526177, PMID 39810840, PMID 39907035, PMID 40340830, PMID 40341124, PMID 40452026, PMID 40554667, PMID 40830709, PMID 41023216, PMID 41457289, PMID 41495607, PMID 41592243, PMID 41760643, PMID 41819560, PMID 42346219, PMID 42371751, PMID 42777290
2017 (3), 2019 (2), 2018 (1), 2023 (1), U19CA021239 (1)